title: Outcome of open antireflux surgery as assessed in a Nordic multicentre prospective clinical trial. Nordic GORD-Study Group.
abstract: OBJECTIVE
  To evaluate the outcome of antireflux surgery in various hospitals in Scandinavian countries.
  
  
  METHODS
  Partly randomised controlled study, and partly open study.
  
  
  METHODS
  Hospitals throughout Norway, Sweden, Denmark and Finland.
  
  
  METHODS
  310 patients with chronic reflux disease and oesophagitis who were initially entered into a randomised controlled study of omeprazole and antireflux surgery.
  
  
  METHODS
  Total fundic wrap, partial fundoplication, or omeprazole.
  
  
  METHODS
  Control of symptoms at one year.
  
  
  RESULTS
  154 patients who had their symptoms of reflux completely controlled with omeprazole were initially randomised to have an open operation but 10 refused, leaving 144 for analysis. 34 patients who had only a partial response were also offered operation; 120/178 (68%) had a total fundic wrap, and 53 (30%) partial fundoplication. 6 patients had postoperative complications that required reoperation and 123 made a completely uneventful recovery. Reflux was controlled in most patients, and only 10 (6%) required further treatment with omeprazole. The outcome in those patients who only responded partially to omeprazole was similar to that in patients who had a complete response.
  
  
  CONCLUSIONS
  The outcome of antireflux surgery throughout Norway, Sweden, Denmark, and Finland is good.
authors.affiliation: Department of Surgery, Sahlgren's University Hospital, Göteborg, Sweden.
authors.forename: L
authors.initials: L
authors.lastname: Lundell
authors.forename: J
authors.initials: J
authors.lastname: Dalenbäck
authors.forename: J
authors.initials: J
authors.lastname: Hattlebakk
authors.forename: E
authors.initials: E
authors.lastname: Janatuinen
authors.forename: K
authors.initials: K
authors.lastname: Levander
authors.forename: P
authors.initials: P
authors.lastname: Miettinen
authors.forename: H E
authors.initials: HE
authors.lastname: Myrvold
authors.forename: S A
authors.initials: SA
authors.lastname: Pedersen
authors.forename: K
authors.initials: K
authors.lastname: Thor
authors.forename: O
authors.initials: O
authors.lastname: Junghard
authors.forename: A
authors.initials: A
authors.lastname: Andersson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002908:Chronic Disease; D005260:Female; D005387:Finland; D005764:Gastroesophageal Reflux / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use; D011446:Prospective Studies; D012537:Scandinavian and Nordic Countries; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D009853:Omeprazole